Nxstage Medical (NXTM) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
NxStage Medical (NXTM) PT Lowered to $33 at Jefferies
May 10, 2017 9:55 AM EDTJefferies lowered its price target on NxStage Medical (NASDAQ: NXTM) to $33.00 (from $38.00) while maintaining a Buy rating.
NXTM had endorsed an outlook that called for sales to increase from $366mn in 2016 to $700mn in 2020, a CAGR of +18%. Management hasnt changed its... More
NxStage Medical (NXTM) PT Lowered to $30 at Canaccord Genuity
May 10, 2017 8:54 AM EDTCanaccord Genuity lowered its price target on NxStage Medical (NASDAQ: NXTM) to $30.00 (from $32.00) while maintaining a Buy rating. NxStage reported 1Q results with revenue of $96.8M above the Street's expectations of $95.3M. EPS came in at $(0.02) and was in line with consensus... More
